So first the “less good” news … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: OPKO, point of care, PSA, Sangia, test | 6 Comments »
-
-
-
-
-
-
- The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of
Awards
Other PCI web sites
-
Disclaimer
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
-
Hot Posts …
- First of six FREE webinars on making well-informed prostate cancer decisions
- First clinical trial of Lu-177-PSMA-617 in recurrent, hormone-sensitive men
- A revolutionary advance in patient-centric prostate cancer advocacy/support
- Are we closer to automated pathological assessment of prostate cancer biopsy slides?
- Lutetium-177 PSMA-617 in treatment of mCRPC: trial results
- Active surveillance and related research: a new research initiative
- Modulating personal bias in provision of prostate cancer “support” services
- How does your doctor do prostate biopsies?
- Major new survey on active surveillance and prostate cancer
- Xofigo 2.0
- Another new urine test for risk of prostate cancer
- Lu-177-PSMA-617 vs Jevtana (cabazitaxel): which should I do next?
- AS and management of Grade Group 2 prostate cancer
- Risk for and detection of clinically significant prostate cancer in previously unbiopsied patients
- ADT and risk for COVID-19 infection?
… and Archives
Blog at WordPress.com. WP Designer.
